AU2009228866A1 - Glucagon receptor antagonists - Google Patents

Glucagon receptor antagonists Download PDF

Info

Publication number
AU2009228866A1
AU2009228866A1 AU2009228866A AU2009228866A AU2009228866A1 AU 2009228866 A1 AU2009228866 A1 AU 2009228866A1 AU 2009228866 A AU2009228866 A AU 2009228866A AU 2009228866 A AU2009228866 A AU 2009228866A AU 2009228866 A1 AU2009228866 A1 AU 2009228866A1
Authority
AU
Australia
Prior art keywords
ser
leu
val
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009228866A
Other languages
English (en)
Inventor
Andrew Ihor Korytko
Rohn Lee Junior Millican
Brian John Ondek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40794248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009228866(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2009228866A1 publication Critical patent/AU2009228866A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009228866A 2008-03-27 2009-03-17 Glucagon receptor antagonists Abandoned AU2009228866A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3990708P 2008-03-27 2008-03-27
US61/039,907 2008-03-27
PCT/US2009/037349 WO2009120530A1 (en) 2008-03-27 2009-03-17 Glucagon receptor antagonists

Publications (1)

Publication Number Publication Date
AU2009228866A1 true AU2009228866A1 (en) 2009-10-01

Family

ID=40794248

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009228866A Abandoned AU2009228866A1 (en) 2008-03-27 2009-03-17 Glucagon receptor antagonists

Country Status (15)

Country Link
US (2) US7968686B2 (https=)
EP (1) EP2268670A1 (https=)
JP (1) JP5438095B2 (https=)
KR (1) KR101235934B1 (https=)
CN (1) CN101983208A (https=)
AR (1) AR070844A1 (https=)
AU (1) AU2009228866A1 (https=)
BR (1) BRPI0910118A2 (https=)
CA (1) CA2719761A1 (https=)
CL (1) CL2009000586A1 (https=)
EA (1) EA201071126A1 (https=)
MX (1) MX2010010517A (https=)
PE (1) PE20091674A1 (https=)
TW (1) TW201000126A (https=)
WO (1) WO2009120530A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120056800A (ko) * 2009-09-08 2012-06-04 (주)네오팜 글루글루카곤 수용체에 대한 항체와 이의 사용
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
EP2785740A1 (en) 2011-12-02 2014-10-08 Eli Lilly and Company Anti-glucagon antibodies and uses thereof
WO2014181229A2 (en) * 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
WO2015189698A2 (en) * 2014-06-08 2015-12-17 Beijing Cosci-Remd Bio Med Tech Company Ltd Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
NZ750953A (en) 2016-08-30 2026-02-27 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
EP3573651A4 (en) * 2017-01-27 2020-10-14 NGM Biopharmaceuticals, Inc. GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
CN115947849A (zh) 2018-12-21 2023-04-11 江苏恒瑞医药股份有限公司 双特异性蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
HU219674B (hu) 1992-08-28 2001-06-28 Novo Nordisk A/S Glukagon-receptort kódoló DNS-molekulák, glukagon-receptor peptidek, glukagon-receptort blokkoló monoklonális ellenanyagok, és eljárások előállításukra
AU2002239538A1 (en) 2000-12-06 2002-06-18 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
AR036711A1 (es) * 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
WO2008003641A1 (en) 2006-07-04 2008-01-10 Bracco Imaging S.P.A. Device for localized thermal ablation of biological tissue, particularly tumoral tissues or the like
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Also Published As

Publication number Publication date
US7968686B2 (en) 2011-06-28
EP2268670A1 (en) 2011-01-05
BRPI0910118A2 (pt) 2015-12-29
JP5438095B2 (ja) 2014-03-12
WO2009120530A1 (en) 2009-10-01
US20110212092A1 (en) 2011-09-01
EA201071126A1 (ru) 2011-04-29
PE20091674A1 (es) 2009-11-04
MX2010010517A (es) 2010-12-20
TW201000126A (en) 2010-01-01
CL2009000586A1 (es) 2010-06-04
KR20100117130A (ko) 2010-11-02
US20090252727A1 (en) 2009-10-08
JP2011518125A (ja) 2011-06-23
AR070844A1 (es) 2010-05-05
CA2719761A1 (en) 2009-10-01
CN101983208A (zh) 2011-03-02
KR101235934B1 (ko) 2013-02-21

Similar Documents

Publication Publication Date Title
KR101235934B1 (ko) 글루카곤 수용체 길항제
US12252536B2 (en) Caninized antibodies
US20240218076A1 (en) Therapeutic antibodies
CN110678484B (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
US9073999B2 (en) Anti-IL-17 receptor A neutralizing antibodies
JP2021036912A (ja) ヒトｃｇｒｐ受容体結合タンパク質
KR20190093658A (ko) 그렘린-1 결정 구조 및 억제 항체
TW201922798A (zh) 靶向rankl的治療性抗體
CA3239307A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha 1
TR201816428T4 (tr) Terapötik antikorlar.
EA050842B1 (ru) Антитела, которые индуцируют fgf21-опосредованную передачу сигнала

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application